Cargando…
Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities
Nearly a billion people worldwide are infected with the hepatitis B Virus (HBV) and about a third of them have chronic infection. HBV is an important cause of morbidity and mortality, including acute and chronic hepatitis and hepatocellular carcinoma (HCC). Screening and control of primary HBV infec...
Autores principales: | Rosenberg, Maya, Poluch, Maria, Thomas, Colin, Sindaco, Paola, Khoo, Alan, Porcu, Pierluigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623156/ https://www.ncbi.nlm.nih.gov/pubmed/37927464 http://dx.doi.org/10.3389/fonc.2023.1275800 |
Ejemplares similares
-
Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
por: Thomas, Colin, et al.
Publicado: (2023) -
Targeting the Bcl-2 Family in B Cell Lymphoma
por: Adams, Clare M., et al.
Publicado: (2019) -
Unmet need in chronic hepatitis B management
por: Liang, Lilian Yan, et al.
Publicado: (2019) -
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
por: Belluomini, Lorenzo, et al.
Publicado: (2022) -
Editorial: Murine Models of Leukemia and Lymphoma
por: Cutucache, Christine E., et al.
Publicado: (2017)